| [1] |
Hoff KV, Hinkes B, Gerber NU, et al. Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT’91[J]. Eur J Cancer, 2009, 45(7): 1209-1217.
|
| [2] |
Chang CH, Housepian EM, Herbert C Jr. An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas[J]. Radiology, 1969, 93(6): 1351-1359.
|
| [3] |
Ramaswamy V, Remke M, Bouffet E, et al. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus[J]. Acta Neuropathol, 2016, 131(6): 821-831.
|
| [4] |
Jiang T, Zhang Y, Wang J, et al. Impact of tumor location and fourth ventricle infiltration in medulloblastoma[J]. Acta Neurochir (Wien), 2016, 158(6): 1187-1195.
|
| [5] |
Bokun J, Grujicic D, Skender-Gazibara M, et al. Management and treatment of children with medulloblastoma in Serbia, a middle-income country[J]. J BUON, 2018, 23(4): 1156-1162.
|
| [6] |
Rutkowski S, von Hoff K, Emser A, et al. Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis[J]. J Clin Oncol, 2010, 28(33): 4961-4968.
|
| [7] |
Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial[J]. Lancet Oncol, 2006, 7(10): 813-820.
|
| [8] |
Ellison DW, Kocak M, Dalton J, et al. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables[J]. J Clin Oncol, 2011, 29(11): 1400-1407.
|
| [9] |
Taylor MD, Northcott PA, Korshunov A, et al. Molecular subgroups of medulloblastoma: the current consensus[J]. Acta Neuropathol, 2012, 123(4): 465-472.
|
| [10] |
Tarbell NJ, Friedman H, Polkinghorn WR, et al. High-risk medulloblastoma: a pediatric oncology group randomized trial of chemotherapy before or after radiation therapy (POG 9031)[J]. J Clin Oncol, 2013, 31(23): 2936-2941.
|
| [11] |
Gandola L, Massimino M, Cefalo G, et al. Hyperfractionated accelerated radiotherapy in the milan strategy for metastatic medulloblastoma[J]. J Clin Oncol, 2009, 27(4): 566-571.
|
| [12] |
Hovestadt V, Smith KS, Bihannic L, et al. Resolving medulloblastoma cellular architecture by single-cell genomics[J]. Nature, 2019, 572(7767): 74-79.
|
| [13] |
Neumann JE, Swartling FJ, Schüller U. Medulloblastoma: experimental models and reality[J]. Acta Neuropathol, 2017, 134(5): 679-689.
|
| [14] |
Kumar V, Kumar V, McGuire T, et al. Challenges and recent advances in medulloblastoma therapy[J]. Trends Pharmacol Sci, 2017, 38(12): 1061-1084.
|
| [15] |
Hammoud H, Saker Z, Harati H, et al. Drug repurposing in medulloblastoma: challenges and recommendations[J]. Curr Treat Options Oncol, 2020, 22(1): 6.
|